Research ExplorerPublicationsCD34(+)-selected stem cell boost without further conditionin...

CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies

Standard

CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. / Klyuchnikov, Evgeny; El-Cheikh, Jean; Sputtek, Andreas; Lioznov, Michael; Calmels, Boris; Furst, Sabine; Chabannon, Christian; Crocchiolo, Roberto; Lemarié, Claude; Faucher, Catherine; Bacher, Ulrike; Alchalby, Haefaa; Stübig, Thomas; Wolschke, Christine; Ayuketang, Francis Ayuk; Reckhaus, Marie-Luise; Blaise, Didier; Kröger, Nicolaus-Martin.

In: BIOL BLOOD MARROW TR, Vol. 20, No. 3, 01.03.2014, p. 382-6.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Klyuchnikov, E, El-Cheikh, J, Sputtek, A, Lioznov, M, Calmels, B, Furst, S, Chabannon, C, Crocchiolo, R, Lemarié, C, Faucher, C, Bacher, U, Alchalby, H, Stübig, T, Wolschke, C, Ayuketang, FA, Reckhaus, M-L, Blaise, D & Kröger, N-M 2014, 'CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies', BIOL BLOOD MARROW TR, vol. 20, no. 3, pp. 382-6. https://doi.org/10.1016/j.bbmt.2013.11.034

APA

Klyuchnikov, E., El-Cheikh, J., Sputtek, A., Lioznov, M., Calmels, B., Furst, S., Chabannon, C., Crocchiolo, R., Lemarié, C., Faucher, C., Bacher, U., Alchalby, H., Stübig, T., Wolschke, C., Ayuketang, F. A., Reckhaus, M-L., Blaise, D., & Kröger, N-M. (2014). CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. BIOL BLOOD MARROW TR, 20(3), 382-6. https://doi.org/10.1016/j.bbmt.2013.11.034

Vancouver

Klyuchnikov E, El-Cheikh J, Sputtek A, Lioznov M, Calmels B, Furst S et al. CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. BIOL BLOOD MARROW TR. 2014 Mar 1;20(3):382-6. https://doi.org/10.1016/j.bbmt.2013.11.034

Bibtex

@article{f7692e7e421045a2870f7ec8224d8799,
title = "CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies",
abstract = "We retrospectively analyzed outcomes of a CD34(+)-selected stem cell boost (SCB) without prior conditioning in 32 patients (male/22; median age of 54 years; range, 20 to 69) with poor graft function, defined as neutrophils ≤1.5 x 10(9)/L, and/or platelets ≤30 x 10(9)/L, and/or hemoglobin ≤8.5 g/dL). The median interval between stem cell transplantation and SCB was 5 months (range, 2 to 228). The median number of CD34(+) and CD3(+) cells were 3.4 x 10(6)/kg (.96 to 8.30) and 9 x 10(3)/kg body weight (range, 2 to 70), respectively. Hematological improvement was observed in 81% of patients and noted after a median of 30 days (range, 14 to 120) after SCB. The recipients of related grafts responded faster than recipients of unrelated grafts (20 versus 30 days, P = .04). The cumulative incidence of acute (grade II to IV) and chronic graft-versus-host disease (GVHD) after SCB was 17% and 26%, respectively. Patients with acute GVHD received a higher median CD3(+) cell dose. The 2-year probability of overall survival was 45%. We suggest that SCB represents an effective approach to improve poor graft function post transplantation, but optimal timing of SCB administration, anti-infective, and GVHD prophylaxis needs further evaluation.",
author = "Evgeny Klyuchnikov and Jean El-Cheikh and Andreas Sputtek and Michael Lioznov and Boris Calmels and Sabine Furst and Christian Chabannon and Roberto Crocchiolo and Claude Lemari{\'e} and Catherine Faucher and Ulrike Bacher and Haefaa Alchalby and Thomas St{\"u}big and Christine Wolschke and Ayuketang, {Francis Ayuk} and Marie-Luise Reckhaus and Didier Blaise and Nicolaus-Martin Kr{\"o}ger",
note = "Copyright {\textcopyright} 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.",
year = "2014",
month = mar,
day = "1",
doi = "10.1016/j.bbmt.2013.11.034",
language = "English",
volume = "20",
pages = "382--6",
journal = "BIOL BLOOD MARROW TR",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies

AU - Klyuchnikov, Evgeny

AU - El-Cheikh, Jean

AU - Sputtek, Andreas

AU - Lioznov, Michael

AU - Calmels, Boris

AU - Furst, Sabine

AU - Chabannon, Christian

AU - Crocchiolo, Roberto

AU - Lemarié, Claude

AU - Faucher, Catherine

AU - Bacher, Ulrike

AU - Alchalby, Haefaa

AU - Stübig, Thomas

AU - Wolschke, Christine

AU - Ayuketang, Francis Ayuk

AU - Reckhaus, Marie-Luise

AU - Blaise, Didier

AU - Kröger, Nicolaus-Martin

N1 - Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

PY - 2014/3/1

Y1 - 2014/3/1

N2 - We retrospectively analyzed outcomes of a CD34(+)-selected stem cell boost (SCB) without prior conditioning in 32 patients (male/22; median age of 54 years; range, 20 to 69) with poor graft function, defined as neutrophils ≤1.5 x 10(9)/L, and/or platelets ≤30 x 10(9)/L, and/or hemoglobin ≤8.5 g/dL). The median interval between stem cell transplantation and SCB was 5 months (range, 2 to 228). The median number of CD34(+) and CD3(+) cells were 3.4 x 10(6)/kg (.96 to 8.30) and 9 x 10(3)/kg body weight (range, 2 to 70), respectively. Hematological improvement was observed in 81% of patients and noted after a median of 30 days (range, 14 to 120) after SCB. The recipients of related grafts responded faster than recipients of unrelated grafts (20 versus 30 days, P = .04). The cumulative incidence of acute (grade II to IV) and chronic graft-versus-host disease (GVHD) after SCB was 17% and 26%, respectively. Patients with acute GVHD received a higher median CD3(+) cell dose. The 2-year probability of overall survival was 45%. We suggest that SCB represents an effective approach to improve poor graft function post transplantation, but optimal timing of SCB administration, anti-infective, and GVHD prophylaxis needs further evaluation.

AB - We retrospectively analyzed outcomes of a CD34(+)-selected stem cell boost (SCB) without prior conditioning in 32 patients (male/22; median age of 54 years; range, 20 to 69) with poor graft function, defined as neutrophils ≤1.5 x 10(9)/L, and/or platelets ≤30 x 10(9)/L, and/or hemoglobin ≤8.5 g/dL). The median interval between stem cell transplantation and SCB was 5 months (range, 2 to 228). The median number of CD34(+) and CD3(+) cells were 3.4 x 10(6)/kg (.96 to 8.30) and 9 x 10(3)/kg body weight (range, 2 to 70), respectively. Hematological improvement was observed in 81% of patients and noted after a median of 30 days (range, 14 to 120) after SCB. The recipients of related grafts responded faster than recipients of unrelated grafts (20 versus 30 days, P = .04). The cumulative incidence of acute (grade II to IV) and chronic graft-versus-host disease (GVHD) after SCB was 17% and 26%, respectively. Patients with acute GVHD received a higher median CD3(+) cell dose. The 2-year probability of overall survival was 45%. We suggest that SCB represents an effective approach to improve poor graft function post transplantation, but optimal timing of SCB administration, anti-infective, and GVHD prophylaxis needs further evaluation.

U2 - 10.1016/j.bbmt.2013.11.034

DO - 10.1016/j.bbmt.2013.11.034

M3 - SCORING: Journal article

C2 - 24321747

VL - 20

SP - 382

EP - 386

JO - BIOL BLOOD MARROW TR

JF - BIOL BLOOD MARROW TR

SN - 1083-8791

IS - 3

ER -